Piper Jaffray Remains Bullish on Nevro (NVRO) Following 2Q Beat and Raise

August 9, 2016 8:23 AM EDT
Get Alerts NVRO Hot Sheet
Price: $76.38 -2.4%

Rating Summary:
    10 Buy, 1 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 21 | Down: 36 | New: 11
Trade NVRO Now!
Join SI Premium – FREE

Find out which companies are about to raise their dividend well before the news hits the Street with StreetInsider.com's Dividend Insider Elite. Sign-up for a FREE trial here.

Piper Jaffray reiterated an Overweight rating on Nevro Corp (NYSE: NVRO), and raised the price target to $112.00 (from $98.00), following the company's 2Q earnings report. 2Q16 revenues were $55.4 million, primarily due to the ongoing launch of HF10 therapy in the United States. Full-year 2016 revenue guidance was raised by $35M to $210-220M from prior $175-185M.

Analyst Brooks West commented, "Nevro reported 2Q16 revenue of $55.4M (+385%) on a 33% sequential increase in US revenue to $40.6M. Management estimates that its HF10 therapy now has 13% global market share and 10% US market share, respectively, as it completes its first full year of US launch of the HF10 therapy. International revenue also remained strong at +33% cc. Full-year 2016 revenue guidance was raised by $35M to $210-220M from prior $175-185M. Sales rep hiring continues at a torrid pace with NVRO adding 27 reps in the quarter to bring its total to 140. Importantly, management lowered its expectation for reps reaching their full productivity range of $1.3-1.5M to 12-15 months from prior 18-24 months as productivity continues to be positively impacted by rapid uptake from early adopter accounts. Reiterate OW rating and raising PT to $112."

For an analyst ratings summary and ratings history on Nevro Corp click here. For more ratings news on Nevro Corp click here.

Shares of Nevro Corp closed at $80.94 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Analyst Comments, Analyst EPS Change, Analyst EPS View, Analyst PT Change

Related Entities

Piper Jaffray, Earnings, Brooks West

Add Your Comment